RxDoctor Payments Data

Ravneet Singh, MD

Family Medicine · Highland, CANPI 1568491066

Payments from drug & device makers

$9,816in general payments, 2019–2025

Across 255 payments — averaging $38.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$6K
  • AbbVie$663
  • Abbott$461
  • Novo Nordisk$365
  • AstraZeneca$354
  • Lilly USA, LLC$297
  • plus $2K from 18 others

What the payments were for

  • Speaking & faculty fees$4,73048%
  • Travel & lodging$1,09811%
  • Food & beverage$3,97741%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,816 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$22,633
Medicare patients
100
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin151$134,013
EliquisApixaban53$35,997
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$29,949
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$25,890
TradjentaLinagliptin25$19,086
Breo ElliptaFluticasone/Vilanterol39$18,614
OzempicSemaglutide17$16,450
XareltoRivaroxaban25$14,294
EntrestoSacubitril/Valsartan17$13,703
JanumetSitagliptin Phos/Metformin Hcl16$12,039
TrintellixVortioxetine Hydrobromide21$11,706
MounjaroTirzepatide11$11,666
Atorvastatin Calcium546$5,129
Febuxostat14$3,296
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$153$153,099176 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$44$74,452124 claims
PfizerEliquis$236$35,99753 claims
Novo NordiskOzempic$365$16,45017 claims
Johnson & JohnsonXarelto$6,043$14,29425 claims
MerckJanumet$234$12,03916 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$53$11,70621 claims
Lilly USA, LLCMounjaro$297$11,66611 claims
AbbVieSynthroid$663$2,51734 claims
Sanofi-aventis U.S. LLCLantus$169$1,42317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Highland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →